Actively Recruiting
Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders Trial
Led by Wake Forest University Health Sciences · Updated on 2026-02-27
130
Participants Needed
1
Research Sites
242 weeks
Total Duration
On this page
Sponsors
W
Wake Forest University Health Sciences
Lead Sponsor
N
National Institutes of Health (NIH)
Collaborating Sponsor
AI-Summary
What this Trial Is About
Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders (EMERALD) is a protocolized intervention based on American College of Cardiology/American Heart Association and US Preventive Services Task Force guidelines designed to initiate preventive cardiovascular care for emergency department patients being evaluated for acute coronary syndrome. The overarching goals of this proposal are to (1) determine the efficacy of EMERALD at lowering low-density lipoprotein cholesterol (LDL-C) and non high-density lipoprotein cholesterol (non-HDL-C) among at-risk Emergency Department (ED) patients who are not already receiving guideline-directed outpatient preventive care and (2) inform our understanding of patient adherence and determinants of implementation for ED-based cardiovascular disease prevention strategies.
CONDITIONS
Official Title
Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders Trial
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Being evaluated for acute coronary syndrome
- Age between 40 and 75 years
- 10-year ASCVD risk of 7.5% or higher, or known diabetes, or known ASCVD (including myocardial infarction, unstable angina, coronary interventions, stroke, transient ischemic attack, or peripheral artery disease)
You will not qualify if you...
- ST-segment elevation myocardial infarction (STEMI) activation
- ST depression greater than 1 mm in contiguous leads
- Currently on lipid-lowering agents such as statins, PCSK9 inhibitors, bempedoic acid, ezetimibe, or inclisiran
- Unable to return for a 30-day follow-up visit
- Unstable vital signs (systolic blood pressure below 90, heart rate above 120 or below 50, oxygen saturation below 90%)
- Statin intolerance
- High-sensitivity troponin I result of 100 ng/L or higher
- End-stage renal disease or glomerular filtration rate below 30 mL/min/1.73 m2
- Liver cirrhosis
- Pregnancy
- Anticipated hospitalization
- Life expectancy less than 1 year
- Transfer from another hospital
- Prisoner status
- Non-English speaking
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Wake Forest University Health Sciences
Winston-Salem, North Carolina, United States, 27517
Actively Recruiting
Research Team
L
Lauren Koehler
CONTACT
N
Nick Ashburn
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here